Key result
PDZK1 overexpression significantly reduces blood pressure and aortic wall thickness in hypertensive ovariectomized mice.
Why the study?
Estrogen deficiency is a major risk factor for postmenopausal hypertension, but the interaction between PDZK1 and beta2-AR in regulating vascular function had not been characterized in estrogen-deficient hypertension.
Does PDZK1 overexpression improve blood pressure, vascular remodeling, and endothelial function via the β2-AR/ERK1/2/c-Fos signaling pathway in ovariectomized mice with angiotensin II-induced hypertension?
Does PDZK1 overexpression improve blood pressure, vascular remodeling, and endothelial function via the β2-AR/ERK1/2/c-Fos signaling pathway in ovariectomized mice with angiotensin II-induced hypertension?
This preclinical study identifies the PDZK1/β2-AR/ERK1/2/c-Fos signaling axis as a key protector of endothelial function that becomes downregulated during estrogen deficiency, suggesting PDZK1 as a novel therapeutic target for postmenopausal hypertension.
Answers are grounded in this paper and cite their sources.
PDZK1 overexpression attenuates hypertension and remodeling in this model; leaves open translation to postmenopausal hypertension.
BACKGROUND: Estrogen deficiency is a major risk factor for postmenopausal hypertension. PDZK1, an estrogen-responsive scaffold protein, may interact with the β2-adrenergic receptor (β2-AR) to regulate vascular function, but this axis has not been characterized in the context of estrogen-deficient hypertension. METHODS: We used ovariectomized and PDZK1 knockout mice infused with angiotensin II to model hypertension in vivo, and HUVECs for mechanistic studies in vitro. Techniques included hemodynamic measurements, histology, molecular interaction assay, chromatin immunoprecipitation, and functional cellular assays. RESULTS: Ovariectomy exacerbated Ang II-induced hypertension and vascular remodeling, which correlated with reduced PDZK1 expression. PDZK1 KO mice showed enhanced hypertensive responses and impaired endothelium-dependent relaxation. Mechanistically, PDZK1 interacted with β2-AR via its PDZ1 and PDZ4 domains, stabilizing β2-AR and activating the downstream ERK1/2/c-Fos pathway to promote endothelial proliferation. PDZK1 knockdown or β2-AR inhibition attenuated this signaling and suppressed endothelial repair. CONCLUSION: Our study identifies a novel PDZK1/β2-AR/ERK1/2/c-Fos axis that is essential for maintaining endothelial function under estrogen-sufficient conditions. Disruption of this pathway in the context of estrogen deficiency contributes to hypertension, highlighting PDZK1 as a potential therapeutic target for postmenopausal hypertension.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Estrogen-deficient angiotensin II-induced hypertension (n=24). Ovariectomy, PDZK1 knockout/overexpression (AAV-OE-PDZK1), and angiotensin II infusion vs. Saline infusion control, sham/intact mice, or negative control virus (AAV-OE-NC) was evaluated on Systolic blood pressure (SBP), mean arterial pressure (MAP), thoracic aortic wall thickness, and endothelium-dependent relaxation (p=<0.0001). PDZK1 overexpression reduced systolic blood pressure, mean arterial pressure, and aortic wall thickness in ovariectomized mice with angiotensin II-induced hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: